AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29145771
Drug: Petroleum gel
RxNorm normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Petroleum gel
Trial: 23113482
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5 mg intravenous infusion at baseline and 12 months)
Trial: 20166859
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone patch (TTP, 300 microg/day)
Trial: 12122534
Drug: Insufflation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insufflation of 10 ml/kg air into the stomach
Trial: 8703663
Drug: rilmenidine 1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rilmenidine 1-2 mg day-1
Trial: 8703663
Drug: atenolol 50-100
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol 50-100 mg day-1
Trial: 19954718
Drug: Raloxifene hydrochloride
RxNorm normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene hydrochloride (60 mg/day, three times per week) for 1 year
Trial: 17300851
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/m2) plus Vinorelbine (25 mg/m2) bi-weekly
Trial: 15167676
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg until the day before surgery)
Trial: 15167676
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no aspirin or discontinued >5 days before surgery)
Trial: 11316974
Drug: 375 mg/day
RxNorm normalized name: estradiol 0.0375 MG/DayTransdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg/day of orally administered flutamide combined with leuprorelin (initiated on the day of leuprorelin injection)
Trial: 11316974
Drug: 375 mg/day
RxNorm normalized name: estradiol 0.0375 MG/DayTransdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg/day of orally administered flutamide combined with leuprorelin (initiated 1 week before leuprorelin injection)
Trial: 11316974
Drug: 375 mg/day
RxNorm normalized name: estradiol 0.0375 MG/DayTransdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg/day of orally administered flutamide combined with leuprorelin (initiated 2 weeks before leuprorelin injection)
Trial: 11316974
Drug: 375 mg/day
RxNorm normalized name: estradiol 0.0375 MG/DayTransdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg/day of orally administered flutamide combined with leuprorelin (initiated 4 weeks before leuprorelin injection)
Trial: 11316974
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 3.75 mg leuprorelin acetate depot alone
Trial: 7943592
Drug: No octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No octreotide treatment (21 patients)
Trial: 3581491
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg betahistine
Trial: 26916927
Drug: Standardized physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized physical therapy exercise intervention
Trial: 8368552
Drug: Nalbuphine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (5 mg)
Trial: 18201935
Drug: Morphine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (4 mg)
Trial: 15734854
Drug: DHEA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (50 mg daily for 12 weeks)
Trial: 12551868
Drug: abciximab (24-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abciximab (24-hour infusion)
Trial: 12551868
Drug: abciximab (48-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abciximab (48-hour infusion) in patients with negative troponin
Trial: 12551868
Drug: abciximab (48-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abciximab (48-hour infusion) in patients with elevated C-reactive protein
Trial: 10383508
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.d. and clarithromycin 500 mg t.d.s. for 14 days (OC14 group)
Trial: 10383508
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.d., clarithromycin 500 mg b.d. and amoxycillin 1 g b.d. for 7 days (OCA7 group)
Trial: 6831755
Drug: Metronidazole alone
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole alone or in combination with systemic antibiotics
Trial: 30730476
Drug: Group MP
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group MP (300 mg pregabalin orally + IV magnesium sulfate 50 mg/kg)
Trial: 30730476
Drug: Group P
RxNorm normalized name: High mobility group protein HMGI-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group P (300 mg pregabalin orally + placebo IV infusion)
Trial: 30730476
Drug: Group M
RxNorm normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group M (placebo capsule + IV magnesium sulfate 50 mg/kg)
Trial: 30730476
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (placebo capsule + placebo IV infusion)
Trial: 27321385
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg vildagliptin twice daily
Trial: 27321385
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sitagliptin once daily
Trial: 21054461
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg) with Eurycoma longifolia (200 mg)
Trial: 21054461
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg) with placebo (Lactose)
Trial: 9580647
Drug: Intranasal live
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal live attenuated, cold-adapted, trivalent influenzavirus vaccine (one dose)
Trial: 9580647
Drug: Intranasal live
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal live attenuated, cold-adapted, trivalent influenzavirus vaccine (two doses)
Trial: 9580647
Drug: Intranasal live
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal live attenuated, cold-adapted, trivalent influenzavirus vaccine (both regimens)
Trial: 9580647
Drug: Intranasal live
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal live attenuated, cold-adapted influenzavirus vaccine
Trial: 8072261
Drug: Dipyridamole and
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole and aspirin combination
Trial: 8072261
Drug: Dipyridamole and
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole and aspirin
Trial: 2647156
Drug: Intravenous amphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amphetamine infusion (0.3 mg/kg)
Trial: 30670760
Drug: Negative control,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative control, no treatment
Trial: 23095869
Drug: TUTI-16 vaccine
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine / L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine / L1 protein, human papillomavirus type 6 vaccine Prefilled Syringe [Gardasil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TUTI-16 vaccine
Trial: 19235040
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg isoflavones daily
Trial: 19235040
Drug: 140 mg
RxNorm normalized name: caffeine 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 mg isoflavones daily
Trial: 17702736
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Aliskiren 150 mg and Valsartan 160 mg
Trial: 9813387
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg, clarithromycin 250 mg and metronidazole 400 mg (OCM) given three times daily for 10 days
Trial: 9813387
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg and amoxicillin 1 g (OA) given twice daily for 14 days
Trial: 8569256
Drug: Water injection
RxNorm normalized name: electroly,inj/dextrose-water INJECTION AMPUL (ML)
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water injection at Qimen, Riyue, and Juque points
Trial: 26314625
Drug: NBP607 (cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBP607 (cell culture-derived inactivated trivalent influenza vaccine)
Trial: 26314625
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (AgrippalS1, egg-based subunit vaccine)
Trial: 22746145
Drug: Psychosocial circumstances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial circumstances at treatment start
Trial: 19535679
Drug: Glucose solution
RxNorm normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose solution (500-ml intragastric infusion)
Trial: 19535679
Drug: Fructose solution
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose solution (500-ml intragastric infusion)
Trial: 19535679
Drug: Aspartame solution
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame solution (500-ml intragastric infusion)
Trial: 19535679
Drug: Saccharin solution
RxNorm normalized name: Saccharin
DrugBank: Saccharin (DB12418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharin solution (500-ml intragastric infusion)
Trial: 19535679
Drug: Sweeter glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweeter glucose + saccharin solution (500-ml intragastric infusion)
Trial: 19535679
Drug: Quinine solution
RxNorm normalized name: quinine Injectable Solution
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine solution (500-ml intragastric infusion)
Trial: 19535679
Drug: Naringin solution
RxNorm normalized name: Naringin
DrugBank: Naringin (DB16859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naringin solution (500-ml intragastric infusion)
Trial: 17525598
Drug: Continuous intrawound
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intrawound infusion with 300 mg diclofenac
Trial: 17525598
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion with systemic diclofenac (75 mg IV every 12 h for 48 h)
Trial: 17525598
Drug: Local ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local ropivacaine infusion with systemic diclofenac (75 mg IV every 12 h for 48 h)
Trial: 11588535
Drug: Manidipine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manidipine (10-20 mg, once daily)
Trial: 606789
Drug: Killed split
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Killed split or whole bivalent influenza vaccine (A/New Jersey/76-A/Victoria/75)
Trial: 27535276
Drug: Leech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leech therapy (5 leeches applied to the affected knee, once every week for 3 weeks)
Trial: 24728028
Drug: TENS therapy
RxNorm normalized name: Walgreens Electronic TENS Therapy Pain Relief Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS therapy
Trial: 25987441
Drug: Antioxidant vitamin
RxNorm normalized name: antioxidant vitamins with minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant vitamin supplementation (AVS) [vitamins C (500 mg), E (400 IU), beta‐carotene (15,000 IU), zinc (7.5 mg), selenium (50 mg), copper (1 mg), and manganese (2.5 mg)] for 4 weeks
Trial: 22776518
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral intake within 5 days postoperatively
Trial: 22776518
Drug: Late oral
RxNorm normalized name: Adalate Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late oral intake starting from postoperative day 6
Trial: 9441769
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral intake
Trial: 16940981
Drug: Pemetrexed (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (300 to 1,200 mg m(‐2) with FA/VB(12))
Trial: 26164495
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg omeprazole, twice daily for 4 weeks
Trial: 26164495
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg omeprazole, twice daily for an additional 4 weeks
Trial: 24131496
Drug: IMPACT Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMPACT Therapy (HPI)
Trial: 21960073
Drug: TIVA (propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA (propofol at 100‐150 mg/kg/min and remifentanil at 2.0 mg/kg/min)
Trial: 17880950
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose step‐up regimen
Trial: 17880950
Drug: Sequential step‐up/step‐down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential step‐up/step‐down regimen
Trial: 16797240
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg/day and Aspirin 100 mg/day
Trial: 10688831
Drug: Lepirudin (Refludan,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lepirudin (Refludan, bolus: 0.1 mg/kg, infusion: 0.1 mg/kg/h for 5 hours)
Trial: 9354207
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg o.m.
Trial: 16355622
Drug: Fengbei Huayu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fengbei Huayu recipe (FHR) twice a day for 8 weeks
Trial: 16355622
Drug: Conventional hypoglycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional hypoglycemic agents and hypotensor
Trial: 14596580
Drug: Individualized behavioral
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized behavioral treatments
Trial: 11279324
Drug: Captopril (25-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25-75 mg daily)
Trial: 11279324
Drug: Fosinopril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (10-20 mg daily)
Trial: 6337032
Drug: Clonidine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (average 0.24 mg/day)
Trial: 6337032
Drug: Propranolol (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (average 105 mg/day)
Trial: 23094900
Drug: Group II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: 41 ml of levobupivacaine 0.5 % + 1 ml magnesium sulfate (150 mg)
Trial: 23094900
Drug: Group IV:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group IV: 41 ml of levobupivacaine 0.25 % + 1 ml magnesium sulfate (150 mg)
Trial: 23094900
Drug: Group I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: 41 ml of levobupivacaine 0.5 % + 1 ml NaCl 0.9 %
Trial: 23094900
Drug: Group III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III: 41 ml of levobupivacaine 0.25 % + 1 ml NaCl 0.9 %
Trial: 16137437
Drug: Weekly epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly epirubicin
Trial: 10915232
Drug: Diltiazem retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem retard (100-200mg once daily)
Trial: 8864318
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (200 mg to 1600 mg)
Trial: 8864318
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (up to 1600 mg)
Trial: 6432325
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of ketoprofen
Trial: 24661817
Drug: Nebulized heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized heparin
Trial: 9822949
Drug: no-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no-treatment control group
Trial: 7860418
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg of a long-acting GnRH agonist microcapsule formulation (Lupron Depot) on days 1 and 30; 4 mg/day testosterone replacement
Trial: 7860418
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg of a long-acting GnRH agonist microcapsule formulation (Lupron Depot) on days 1 and 30; 8 mg/day testosterone replacement
Trial: 7860418
Drug: Treatment period
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment period (9 weeks)
Trial: 2468962
Drug: PK 11195
RxNorm normalized name: Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PK 11195 (200 mg orally)
Trial: 2468962
Drug: Nicardipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (20 mg orally)
Trial: 2468962
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PK 11195 and Nicardipine
Trial: 25262253
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 mg/d)
Trial: 913294
Drug: Hydrochlorothiazide-triamterene (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide-triamterene (25 and 50 mg/d)
Trial: 6782605
Drug: IV physostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV physostigmine administration
Trial: 27336726
Drug: Ribociclib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib (400 mg/day) plus letrozole (2.5 mg/day)
Trial: 27336726
Drug: Ribociclib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib (600 mg/day) plus letrozole (2.5 mg/day)
Trial: 27336726
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg/day) alone
Trial: 25027304
Drug: Glycopyrronium MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium MDI at 14.4, 28.8, 57.6, and 115.2 μg
Trial: 18577933
Drug: Berlition (contains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berlition (contains a-lipoic acid) used in neuroprotective therapy for chronic brain ischemia
Trial: 15844495
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray 200 mcg twice daily, commencing 6 weeks after FESS
Trial: 10482177
Drug: Intravenous cariporide
RxNorm normalized name: Cariporide
DrugBank: Cariporide (DB06468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cariporide 20 mg every 8 hours
Trial: 10482177
Drug: Intravenous cariporide
RxNorm normalized name: Cariporide
DrugBank: Cariporide (DB06468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cariporide 80 mg every 8 hours
Trial: 10482177
Drug: Intravenous cariporide
RxNorm normalized name: Cariporide
DrugBank: Cariporide (DB06468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cariporide 120 mg every 8 hours
Trial: 10482177
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (cariporide and placebo)
Trial: 29995455
Drug: Rifaximin‐α 550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin‐α 550 mg twice daily plus lactulose
Trial: 27584836
Drug: Medication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication treatment alone (MTA group)
Trial: 19395187
Drug: High-risk patients
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk patients with PRPH-PSA <=0.1 ng/ml
Trial: 1785031
Drug: Ultrasound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound therapy (1.0 watt/cm2 at 1 MHz, for 10 min) twice weekly for 8 weeks
Trial: 6101791
Drug: Human leucocyte
RxNorm normalized name: Human leucocyte antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human leucocyte interferon (12 x 10(6) reference units daily for the first week, then halved weekly for six weeks)
Trial: 19014790
Drug: Contraceptive Patch
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive Patch (CP)
Trial: 10522500
Drug: Topical ascorbic
RxNorm normalized name: ascorbic acid Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ascorbic acid (Cellex‐C high‐potency serum)
Trial: 8746883
Drug: Tibolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (2.5 mg daily) + Calcium (1000 mg daily)
Trial: 15700052
Drug: Calcium (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1000 mg daily)